WO2007030577A3 - Prodrugs of t3 and t4 with enhanced bioavailability - Google Patents

Prodrugs of t3 and t4 with enhanced bioavailability Download PDF

Info

Publication number
WO2007030577A3
WO2007030577A3 PCT/US2006/034790 US2006034790W WO2007030577A3 WO 2007030577 A3 WO2007030577 A3 WO 2007030577A3 US 2006034790 W US2006034790 W US 2006034790W WO 2007030577 A3 WO2007030577 A3 WO 2007030577A3
Authority
WO
WIPO (PCT)
Prior art keywords
prodrugs
peptide
enhanced bioavailability
terminus
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/034790
Other languages
French (fr)
Other versions
WO2007030577A2 (en
Inventor
James Scott Moncrief
Travis Mickle
Lawrence Olon
Thomas Piccariello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New River Pharmaceuticals Inc
Original Assignee
New River Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New River Pharmaceuticals Inc filed Critical New River Pharmaceuticals Inc
Priority to CA002621847A priority Critical patent/CA2621847A1/en
Priority to AU2006287531A priority patent/AU2006287531A1/en
Priority to JP2008530178A priority patent/JP2009507847A/en
Priority to EP06814260A priority patent/EP1929030A2/en
Publication of WO2007030577A2 publication Critical patent/WO2007030577A2/en
Publication of WO2007030577A3 publication Critical patent/WO2007030577A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to compositions of amino acid and peptide conjugates comprising T3 and/or T4. The T3 or T4 is covalently attached to at least one amino acid via the N-terminus, the C-terminus, a side chain of the peptide carrier, and/or interspersed within the peptide chain. Also discussed are methods for protecting and administering active agents and methods for treating thyroid disorders.
PCT/US2006/034790 2005-09-08 2006-09-08 Prodrugs of t3 and t4 with enhanced bioavailability Ceased WO2007030577A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002621847A CA2621847A1 (en) 2005-09-08 2006-09-08 Prodrugs of t3 and t4 with enhanced bioavailability
AU2006287531A AU2006287531A1 (en) 2005-09-08 2006-09-08 Prodrugs of T3 and T4 with enhanced bioavailability
JP2008530178A JP2009507847A (en) 2005-09-08 2006-09-08 Prodrugs of T3 and T4 with enhanced bioavailability
EP06814260A EP1929030A2 (en) 2005-09-08 2006-09-08 Prodrugs of t3 and t4 with enhanced bioavailability

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US71485905P 2005-09-08 2005-09-08
US60/714,859 2005-09-08
US78669506P 2006-03-29 2006-03-29
US60/786,695 2006-03-29
US11/517,582 US20070099841A1 (en) 2005-09-08 2006-09-08 Prodrugs of T3 and T4 with enhanced bioavailability
US11/517,582 2006-09-08

Publications (2)

Publication Number Publication Date
WO2007030577A2 WO2007030577A2 (en) 2007-03-15
WO2007030577A3 true WO2007030577A3 (en) 2007-10-25

Family

ID=37836440

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/034790 Ceased WO2007030577A2 (en) 2005-09-08 2006-09-08 Prodrugs of t3 and t4 with enhanced bioavailability

Country Status (6)

Country Link
US (1) US20070099841A1 (en)
EP (1) EP1929030A2 (en)
JP (1) JP2009507847A (en)
AU (1) AU2006287531A1 (en)
CA (1) CA2621847A1 (en)
WO (1) WO2007030577A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969288B2 (en) 2008-12-19 2015-03-03 Indiana University Research And Technology Corporation Amide based glucagon and superfamily peptide prodrugs

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1565171A4 (en) * 2002-11-05 2010-06-30 Shire Llc Controlled absorption of mixed thyroyd hormone formulations
WO2008057464A2 (en) * 2006-11-01 2008-05-15 King Pharmaceuticals Research And Development, Inc. Compositions and methods for improving the bioavailability of liothyronine
US20110136911A1 (en) * 2007-12-20 2011-06-09 The Feinstein Institute For Medical Research Treatment of sepsis and inhibition of mif by d-t4
US20110065633A1 (en) 2008-01-30 2011-03-17 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
JP2012512898A (en) * 2008-12-19 2012-06-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション Dipeptide bond medicinal agent
EP2453900A1 (en) 2009-07-17 2012-05-23 Shire LLC Novel carbamate amino acid and peptide prodrugs of opioids and uses thereof
EP2461804A4 (en) * 2009-08-04 2013-10-02 Haren Treasurer Greater utility with thyroid hormone
AU2011246851B2 (en) * 2010-04-28 2016-07-21 Osnat Ashur-Fabian Methods, compositions and kits for providing a therapeutic treatment
CA2803164C (en) 2010-06-24 2018-08-21 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
KR20130083843A (en) * 2010-06-24 2013-07-23 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Dipeptide linked medicinal agents
WO2013096596A1 (en) * 2011-12-20 2013-06-27 Latham Keith R Sustained drug release and improved product stability using non-covalent particle coating methods
KR102336426B1 (en) * 2013-11-05 2021-12-08 아스트라제네카 아베 Nmda antagonist prodrugs
KR20250050961A (en) * 2022-08-17 2025-04-15 보스톤 싸이엔티픽 싸이메드 인코포레이티드 Iodinated cross-linked hydrogel and method for forming the same
WO2026019705A1 (en) * 2024-07-15 2026-01-22 Boston Scientific Scimed, Inc. Methods of forming radiopaque peptides for use in medical hydrogels

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087483A1 (en) * 2000-08-22 2004-05-06 New River Pharmaceuticals, Inc. Iodothyronine compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983099A (en) * 1975-03-19 1976-09-28 Micromedic Diagonistics, Inc. Thyroxine-and triiodothyronine-tyrosine dipeptide derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087483A1 (en) * 2000-08-22 2004-05-06 New River Pharmaceuticals, Inc. Iodothyronine compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIRKEGAARD ET AL.: "The Role of Thyroid Hormones in Depression", EUR. J. ENDOCRINOL., vol. 138, no. 1, January 1998 (1998-01-01), pages 1 - 9, XP008126651 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969288B2 (en) 2008-12-19 2015-03-03 Indiana University Research And Technology Corporation Amide based glucagon and superfamily peptide prodrugs

Also Published As

Publication number Publication date
US20070099841A1 (en) 2007-05-03
JP2009507847A (en) 2009-02-26
CA2621847A1 (en) 2007-03-15
AU2006287531A1 (en) 2007-03-15
WO2007030577A2 (en) 2007-03-15
EP1929030A2 (en) 2008-06-11

Similar Documents

Publication Publication Date Title
WO2007047291A3 (en) Anti-glypican-3 antibody
EP2360258A3 (en) Aprotinin polypeptides for transporting a compound across the blood-brain barrier
WO2005046575A3 (en) Amino acid prodrugs
WO2006071613A3 (en) Injectable non-aqueous suspension
WO2006132670A3 (en) Auristatins having an aminobenzoic acid unit at the n terminus
UA90293C2 (en) Process for preparing lansoprazole
NZ593311A (en) Albumin binding peptide-mediated disease targeting
WO2006041641A3 (en) Therapeutic agents with decreased toxicity
WO2006067633A3 (en) Conjugation product
WO2006125539A3 (en) Combination therapy comprising diaryl ureas for treating diseases
WO2007005941A3 (en) Liver targeted conjugates
MX2010004899A (en) Novel neurturin conjugates for pharmaceutical use.
JO2859B1 (en) Peptides and compounds that bind to a receptor
WO2012061113A3 (en) Cancer-targeting peptides and uses thereof in cancer treatment and diagnosis
TW200621160A (en) Anti-termite agent
IL185101A0 (en) Poly-epitope peptide derived from thymidylate synthase having immunological and anti-tumour activity
WO2006096690A3 (en) Compositions and methods for inhibiting g protein signaling
WO2007033099A3 (en) Prodrugs of phentermine
WO2006083927A3 (en) Antimicrobial agent
USD542158S1 (en) Watch case
WO2008021439A3 (en) Compositions and methods for treatment of cardiac hypertrophy
WO2003072047A3 (en) Idothyronine compositions
WO2006101909A3 (en) Combination therapy for treating or preventing diseases
WO2007144492A3 (en) Peptides with anti-proliferative activity
USD527530S1 (en) Brush

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680041560.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 934/KOLNP/2008

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2621847

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008530178

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006287531

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006814260

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006287531

Country of ref document: AU

Date of ref document: 20060908

Kind code of ref document: A